Cidara Therapeutics Inc. (NASDAQ:CDTX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
CDTX Weekly Chart

Old Forum Content for CDTX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • MongosPawn: $CDTX Up pre-market on news. Cidara Therapeutics Announces European Approval of REZZAYO(R) (rezafungin) for the Treatment of Invasive Candidiasis in Adults
  • MongosPawn: $CDTX SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara will also present new preclinical data on CBO421, its first-in-class CD73 targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland.
  • DavidK: $CDTX taking on the shin today . Don’t see any bad news . Someone on board had talked about this in the past . I bought 2k shares as a lottery ticket
  • MongosPawn: @DavidK $CDTX That may have been me a couple of weeks ago pointing out the pre-earnings bounce. I have a few shares. I find no news so today looks like a wash out day of weak hands . . . maybe.
  • DavidK: @MongosPawn $CDTX only research report I have on E*trade shows price estimates for stock from mid 2’s up to upper 6’s . Downside from here only .73 so I like the risk reward .
  • MongosPawn: $CDTX Big pre-earnings bounce over last 2 days. Bumping up against the 50 dma now. Earnings after the bell today.
  • woodman: @bhaden1 $NVDA $ARDX - How biotech stocks function and react is too often irrational. Lots of traders in smid biotech can also push them around. $CDTX is an example of approval being baked in and massive selling after approval. It happens. ARDX alrea ...
  • bhaden1: @woodman $NVDA $ARDX $CDTX Tick Tock..No news. I added a small amount at 3.45.
  • MongosPawn: $CDTX Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults. -- The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.2,3 -- If approved by the European Medicines Agency, rezafungin could be the first new treatment option in over 10 years for patients with invasive candidiasis.4
  • DavidK: @MongosPawn $CDTX thanks for the tip . Picked up 2000 shares .
  • DavidK: @MongosPawn $CDTX read a research report and high 7 low 3 price target for next year .
  • MongosPawn: $CDTX Nice move off of the 50 dma. Can't find any news.
  • MongosPawn: $CDTX Up 26% Today on news. Shares of Cidara Therapeutics rose sharply Wednesday after the biotechnology company said a Johnson & Johnson unit plans to proceed with the development of CD388 for the prevention of influenza A and B. San Diego biotechnology company Cidara said it will receive a $7 million milestone payment from J&J's Janssen unit, which will assume responsibility for future development, manufacturing and commercialization activities of CD388. Cidara, which had signed an influenza license and collaboration agreement with Janssen in 2021, said it is eligible to receive up to an additional $685 million in milestone payments under the deal, along with royalties on product sales.
  • :
  • MongosPawn: $CDTX Up on announcement after market close. EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO , July 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced an update on REZZAYO™ (rezafungin for injection) which was approved by the U.S. Food and Drug Administration (FDA) earlier this year. Earlier today, Cidara’s U.S. partner, Melinta Therapeutics , announced the commercial launch of REZZAYO.
  • MongosPawn: $CDTX
    Cidara Therapeutics Inc (NASDAQ:CDTX) provided an update on the status of its ongoing CD388 program for the prevention of influenza A and B under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals ...
  • bhaden1: $CDTX Cidara receives FDA Fast Track Designation for CD388. https://www.cidara.com/news/cidara-therapeutics-receives-u-s-fda-fast-track-designation-for-cd388-a-novel-drug-fc-conjugate-targeting-influenza-a-and-b/
  • Lou: $CDTX 10:05 AM EDT, 06/22/2023 (MT Newswires) -- Cidara Therapeutics(CDTX) said Thursday the US Food and Drug Administration granted Fast Track Designation to its influenza A and B drug candidate CD388. The drug candidate is being developed for adults at high risk of severe influenza A and B infection, the company said.
  • bhaden1: $CDTX Cidara will present at Immunotherapy conference in Boston.https://finance.yahoo.com/news/cidara-therapeutics-present-adenosine-pathway-120000225.html?.tsrc=rss
  • MongosPawn: $CDTX Trying to break up from a small flag. Long
  • woodman: ...
    Now for what's on my radar: $PDSB $PLX $CDTX. Also, $MCRB - watching but still isn't right. (I'm not around today to take any action on any of these.) These are good ones to look into in terms of doing your due diligence. And, yes, if you are buying ...
  • MongosPawn: $CDTX Nice bounce off of the 21dma. Spec position for me.
  • woodman: $CDTX - HC Wainwright analyst Ed Arce reiterates a Buy and maintains $6 price target.
  • sbw1: @woodman $CDTX maybe that helped it jump.
  • woodman: @sbw1 $CDTX - Yeah, I was wondering that as well.
  • bhaden1: @woodman $CDTX Their quarterly was solid progress. I missed getting burned on the dilution, so am still long from 1.10. $ARDX still largest biotech position. I plan on holding until end of year or beyond depending on news. So far, no reason to sell.
  • bhaden1: @woodman $ARDX It is close to the $4 I mentioned before when I would re-load and sell some $CDTX to purchase. What are your thoughts? This few days sell off makes no sense.
  • Bs7518: @woodman $CDTX Haven't heard much on this lately been holding and added on pull back, Thoughts?
  • Lou: @Bs7518 $CDTX - I have a starter - not holding out much hope, though Fidelity ATP shows that today is earnings date.
  • woodman: @Bs7518 $CDTX - I'm not in it and haven't been following it much post-approval. Now, I guess they'll have to prove they can sell a lot of the drug. My $biotech dollars are taken up by or reserved for other stocks.
  • woodman: @steve71 $PLX - I never had any $MCRB, though it's on my radar. I don't have much interest in buying back $CDTX.
  • bhaden1: $CDTX continues to form a base and just waiting on news. FWIW: According to 6 analyst offering 12-month price targets in the last 3 months, Cidara Therapeutics has an average price target of $5.5 with a high of $6.50 and a low of $3.00.
  • woodman: $CDTX - I like the base and I have been watching it post-approval and $20 mil milestone payment. What specific news are you waiting on?
  • woodman: @bhaden1 $CDTX - I like the base and I have been watching it post-approval and $20 mil milestone payment. What specific news are you waiting on?
  • woodman: $CDTX - Misfire - I tried to post under @bhaden1 post below.
  • bhaden1: @woodman $CDTX updates on approval for Rezafungin for prevention of Invasive Fungal Disease in Blood and Marrow transplant patients and update on Phase 2 trials of CD388 flu shot. Janssen is their worldwide partner for CD388, so they are poised to really get going once it is approved.
  • bhaden1: @woodman $CDTX Also, I am long at 1.10.
  • woodman: @bhaden1 $CDTX - Thanks. Do you know when those updates are expected?
  • bhaden1: @woodman $CDTX I do not. Quarterly earnings call / update?
  • bhaden1: @woodman $CDTX Earnings call around May 10 (projected).
  • Margi1983: @woodman $CDTX Wow..following penny stocks a la Wolf of Wall St.
  • woodman: @bhaden1 $CDTX - Thanks.
  • woodman: @Margi1983 $CDTX - I follow a wide range of stocks. In biotech, particularly, there are some great opportunities in low priced stocks. $ARDX started out essentially as a "penny stock" for me. This stuff certainly isn't for the faint of heart.
  • woodman: @Margi1983 - $CDTX $ARDX - The key, particularly for biotech, is researching and reading as much as you can, and getting guidance from people who are smart about the companies and their therapies and the science. There are no guarantees, of course, but there's also no substitute for rolling up the sleeves and working hard to understand what you are looking at and what you are buying or considering buying. Controlling risk (many ways to do that) is important too.
  • sierramp: @woodman $CDTX $ARDX Definitely not for the faint of heart. I don't like that $ARDX didn't hold at the 21D but it's a generally sucky stock trading day.
  • woodman: @sierramp $CDTX $ARDX - I don't have a position in CDTS and I'm sure if I will get back into it or not. The 200d seems to be beckoning CDTX. As for ARDX, I posted my thoughts in some detail in a different thread above, if interested.
  • sierramp: @woodman $CDTX $ARDX Thank you. I read your post above. I always appreciate your thoughts.
  • woodman: @woodman $CDTX $ARDX - [EDITED (due to errors in the one I posted above - I SO need a working EDIT button)] - I don't have a position in CDTX and I'm not sure if I will get back into it or not. The 200d seems to be beckoning CDTX. As for ARDX, I posted my thoughts in some detail in a different thread above, if interested.
  • bhaden1: @woodman $CDTX $ARDX If $ARDX falls to 4, I will lighten up on $CDTX, even at a small loss, in order to overweight $ARDX. Right now, I am equal weight. I didn't suffer the "surprise" share offering as you did, but completely agree that the risk/reward profile of $ARDX is far more certain than $CDTX. Thank you for your musings and thoughts - as always.
  • woodman: @steve71 $MCRB $VRTX $XERS - Nice work with $MCRB.I never got on board though looked at it a lot. $$ tied up elsewhere so I never really got in gear with it. I think your idea to sell before PDUFA is a good one. Seems that approval is very likely, but the stock still isn't moving as hard as one would hope/expect. I get a $CDTX vibe with it (though MCRB does have much greater institutional support than CDTX did/does). I also think there are some questions about rollout post-approval.
  • MongosPawn: $CDTX Up 11% today. Bounced off of support. Up against the 100 dma now. Long.
  • bhaden1: $cdtx Bounced off of support at $0.95. I am long at 1.10. Currently at 1.13.
  • bhaden1: $CDTX added at 1.23
  • woodman: @bhaden1 $CDTX - I have some that I bought back lower the other day, but I don't want to get over my skis with this one. It hit the 8dEMA and is receding now. I'm leaving early today, so I will miss it if it moves higher from here, but I'm okay just waiting to see what it does from here. If I miss it, I miss it.
  • bhaden1: @woodman $ARDX 100% with you and my largest holding as well. I added on the Pull Back at $CDTX at 1.23. Not sure $CDTX has the fire power of $ARDX, but I like its long term prospects. Thank you for sharing your thoughts and wisdom!
  • bhaden1: @woodman $CDTX Understood. Buying the pullback may or may not work. My first tranche was at 1.10, now 1.23. I am really in it for the long term so not too terribly concerned about swings here. I wonder how the CEO knew to place an order at 1.04?
  • woodman: @bhaden1 $ARDX $CDTX - You're quite welcome. Best of continued luck for all of us!
  • MongosPawn: $CDTX Added.
  • woodman: $CDTX - I started buying this back yesterday. Today is Bounce Day 2 after the very big sell-the-news drop starting on 3/23 when it announced approval of one of its anti-fungal drugs. A number of institutions are in at a higher than current price which makes things kind of interesting. Cantor came out with an Overweight rating and price target of $5 on 3/8, the day after CDTX closed its secondary offering.
  • pperlroth: @woodman $CDTX yes I started buying back yesterday at $1.06. Found support there and hasn't looked back yet
  • bhaden1: $CDTX stabilizing at $1.05 reflecting the additional dilution via the stock sales in first week in March. Pretty nasty surprise to shareholders as they have approx 36ml in the combo of new common shares and convertible shares to common. End of year 2022 they had 75 ml outstanding common.
  • woodman: @bhaden1 $CDTX - It was quite a rude pullback. I managed to lose my profit. No position currently, but looking at it again. They now have lots of cash for Cloudbreak (from the sales but also hundreds of millions for milestone payments from $JNJ/Janssen and not sure who else). Institutions bought much higher). CEO buyback at 1.04 (I wonder if there's some shenanigans there; if so, not a trustworthy CEO). Other stuff in the pipeline with Janssen. https://www.cidara.com/pipeline/
  • woodman: $ARDX $CDTX @bhaden1 - I replied to your posts below where you posted.
  • woodman: @Lou $VKTX $ARDX #TheWoodman - Well, I managed to lose all my profit and took a small loss in $CDTX because I didn't immediately lighten up on approval and waited too long to sell. We all get bitten at times. Lou, plan to buy VKTX back on a dip because it's going to run into NASH data and, I think, do very well with that data in Q2. Also, way to go putting it into ARDX which I think will continue north.
  • woodman: @spmeyers $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics - I think your paramaters for/definition of a break of the 50 day are too precise. The way I look at it, it has held the 50 day.
  • woodman: $TTPH - In a good spot here. Buy the dips, sell the rips on this one. New #Antibiotics bill may pull up the entire antibiotics sector if it gets traction. This is regarded as an important bill. http://www.cidrap.umn.edu/news-perspective/2018/06/bipartisan-bill-proposes-new-pull-incentives-priority-antibiotics Other antibiotics stocks: $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO
  • steve71: @woodman $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics That Prize concept is really interesting. A problem not mentioned is that new antibiotics are often barely used in order to protect them from rapid resistance. Sometimes they are available only in hospital and only after an Infectious Disease consult. With low volumes, it may take a decade to recover development costs. But using the Prize to extend exclusivity on other more profitable drugs is a smart inducement. Would be good to see the potential gains quantified.
  • woodman: @steve71 $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics - Thanks for your thoughts, as always. Check out the intraday chart for TTPH today.
  • spmeyers: @woodman $TTPH $PRTK $MLNT $AKAO $NBRV $MTFB $CDTX $SCYX $SPRO #Antibiotics thx for that list to watch; break of 50-day concerns me on TTPH though
  • woodman: #Antibiotics companies $AKAO $NBRV $TTPH $MTFB $PRTK $MLNT $CDTX $SCYX $SPRO: FDA and CMS under discussion for new reimbursement model to create incentives for the development of novel antimicrobial drugs. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm610503.htm Very interesting news for antibiotics stocks.
  • LTCSteve: Folks, you should consider flipping new IPOs day of open. Day traded 400 shares of $CDTX and $ADRO after open and stopped out with trailing stop for about $2 profit. Allotted 500 shares of $XBIT. Need to hold 15 days IAW Fidelity flipping policy - currently up $4.
  • LTCSteve: @TunaHelper @AlanB #IPO I check in IBD or elsewhere for IPO opening dates. The day or night before the opening, I set an alert for price movement above $5 (the IPOs open at least above $5). I have charts for the stocks already open. I'm already sitting at my desk and when I hear the alert I see price movement for the first minute. I watch for a couple minutes to establish trend. If the trend is up, I buy the stock and set a trailing stop. The trailing stop usually gets triggered an hour or more later. I've been doing this for about three months. Over that time I made about $4k. Today I made over $800 trading $CDTX and $ADRO.
  • LTCSteve: @ogas $CDTX and $ADRO bought aftermarket. $XBIT allotted to me by Fidelity; per Fidelity policy I must hold for 15 calendar days not to violate their IPO flipping policy.
Visit the Trading Forum to join in the discussion.
Stock Price $0.92
Change 0.00%
Volume 1,509,040

Cidara Therapeutics Inc mainly develops anti-infective drugs in the United States. It attends to serious fungal infections through its drug candidates and proprietary immunotherapy technology platform, Cloudbreak.

Request Video of CDTX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!